Limits...
Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma.

Ding H, Jin X, Ding N, Fu Z, Song Y, Zhu J - Cancer Cell Int. (2013)

Bottom Line: One of them, CD20 Exon2 [216] was found to be highly correlated with response to R-CHOP.A trend toward higher complete remission (CR) rate was observed in patients with homozygous C genotype (67.4%) compared with CT plus TT genotype (47.1%) (P = 0.091).The CC genotype at Exon2 [216] appears to be associated with favourable response to R-CHOP.

View Article: PubMed Central - HTML - PubMed

Affiliation: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Central Laboratory, Peking University Cancer Hospital & Institute, Beijing 100142, China.

ABSTRACT

Background: R-CHOP has significantly improved survival rates of patients with diffuse large B cell lymphoma (DLBCL) by ~20% as compared to CHOP. CD20 antigen, highly expressed on more than 80% of B-cell lymphomas, is the target for rituximab. The goal of our study was to examine polymorphism in the CD20 gene in Chinese DLBCL population and whether CD20 gene polymorphism is associated with clinical response to R-CHOP.

Method: CD20 gene polymorphism was detected in the entire coding regions including 6 exons by polymerase chain reaction (PCR)-sequencing assay in 164 patients with DLBCL. Among them, 129 patients treated with R-CHOP as frontline therapy (R ≥ 4 cycles) were assessable for the efficacy.

Results: Polymorphisms at three single nucleotides (SNP) were identified in the entire coding regions of the CD20 gene in the 164 patients. One of them, CD20 Exon2 [216] was found to be highly correlated with response to R-CHOP. Patients with homozygous C genotype showed a trend toward higher overall response rate than others with CT plus TT genotype (90.6% vs. 79.5%; P =0.166). A trend toward higher complete remission (CR) rate was observed in patients with homozygous C genotype (67.4%) compared with CT plus TT genotype (47.1%) (P = 0.091).

Conclusion: These results suggest that there are 3 SNPs in CDS of the CD20 gene in Chinese DLBCL population. The CC genotype at Exon2 [216] appears to be associated with favourable response to R-CHOP.

No MeSH data available.


Related in: MedlinePlus

Disease specific survival (DSS) in DLBCL subjects with CD20 Exon2[216] polymorphism. Kaplan-Meier curve of DSS was plotted by CD20 Exon2 [216] CC and CT plus TT genotype.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3686705&req=5

Figure 2: Disease specific survival (DSS) in DLBCL subjects with CD20 Exon2[216] polymorphism. Kaplan-Meier curve of DSS was plotted by CD20 Exon2 [216] CC and CT plus TT genotype.

Mentions: After a median follow-up time of 524 days (range, 60–2073 days), 32 (25%) patients relapsed or progressed, and 18 (14%) died. Seven patients participated in a clinical trial evaluating everolimus (RAD001) and were censored for PFS analysis. The patients with homozygous C genotype had a median PFS of 465 days (range, 50–1275 days) versus 442 days (range, 41–1255 days) for the rests, but the difference did not reach statistical significance (P = 0.204) (Figure 1). Survival data was available for 123 patients. Six patients were censored for not being died of DLBCL. The DSS was 536 days (range, 143–1364 days) for homozygous C patients, and 571 days (range, 142–1350 days) for T carriers (P = 0.316, Figure 2). This difference was neither statistically significant between GCB and non-GCB lymphoma groups (data not shown).


Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma.

Ding H, Jin X, Ding N, Fu Z, Song Y, Zhu J - Cancer Cell Int. (2013)

Disease specific survival (DSS) in DLBCL subjects with CD20 Exon2[216] polymorphism. Kaplan-Meier curve of DSS was plotted by CD20 Exon2 [216] CC and CT plus TT genotype.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3686705&req=5

Figure 2: Disease specific survival (DSS) in DLBCL subjects with CD20 Exon2[216] polymorphism. Kaplan-Meier curve of DSS was plotted by CD20 Exon2 [216] CC and CT plus TT genotype.
Mentions: After a median follow-up time of 524 days (range, 60–2073 days), 32 (25%) patients relapsed or progressed, and 18 (14%) died. Seven patients participated in a clinical trial evaluating everolimus (RAD001) and were censored for PFS analysis. The patients with homozygous C genotype had a median PFS of 465 days (range, 50–1275 days) versus 442 days (range, 41–1255 days) for the rests, but the difference did not reach statistical significance (P = 0.204) (Figure 1). Survival data was available for 123 patients. Six patients were censored for not being died of DLBCL. The DSS was 536 days (range, 143–1364 days) for homozygous C patients, and 571 days (range, 142–1350 days) for T carriers (P = 0.316, Figure 2). This difference was neither statistically significant between GCB and non-GCB lymphoma groups (data not shown).

Bottom Line: One of them, CD20 Exon2 [216] was found to be highly correlated with response to R-CHOP.A trend toward higher complete remission (CR) rate was observed in patients with homozygous C genotype (67.4%) compared with CT plus TT genotype (47.1%) (P = 0.091).The CC genotype at Exon2 [216] appears to be associated with favourable response to R-CHOP.

View Article: PubMed Central - HTML - PubMed

Affiliation: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Central Laboratory, Peking University Cancer Hospital & Institute, Beijing 100142, China.

ABSTRACT

Background: R-CHOP has significantly improved survival rates of patients with diffuse large B cell lymphoma (DLBCL) by ~20% as compared to CHOP. CD20 antigen, highly expressed on more than 80% of B-cell lymphomas, is the target for rituximab. The goal of our study was to examine polymorphism in the CD20 gene in Chinese DLBCL population and whether CD20 gene polymorphism is associated with clinical response to R-CHOP.

Method: CD20 gene polymorphism was detected in the entire coding regions including 6 exons by polymerase chain reaction (PCR)-sequencing assay in 164 patients with DLBCL. Among them, 129 patients treated with R-CHOP as frontline therapy (R ≥ 4 cycles) were assessable for the efficacy.

Results: Polymorphisms at three single nucleotides (SNP) were identified in the entire coding regions of the CD20 gene in the 164 patients. One of them, CD20 Exon2 [216] was found to be highly correlated with response to R-CHOP. Patients with homozygous C genotype showed a trend toward higher overall response rate than others with CT plus TT genotype (90.6% vs. 79.5%; P =0.166). A trend toward higher complete remission (CR) rate was observed in patients with homozygous C genotype (67.4%) compared with CT plus TT genotype (47.1%) (P = 0.091).

Conclusion: These results suggest that there are 3 SNPs in CDS of the CD20 gene in Chinese DLBCL population. The CC genotype at Exon2 [216] appears to be associated with favourable response to R-CHOP.

No MeSH data available.


Related in: MedlinePlus